Travere Therapeutics
TVTX
131 hedge funds and large institutions have $964M invested in Travere Therapeutics in 2019 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 54 increasing their positions, 38 reducing their positions, and 14 closing their positions.
42% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 38
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
3% more capital invested
Capital invested by funds: $934M → $964M (+$30M)
1% more funds holding
Funds holding: 130 → 131 (+1)
0.03% more ownership
Funds ownership: 102.83% → 102.86% (+0.03%)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
86% less call options, than puts
Call options by funds: $2.32M | Put options by funds: $16.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$14.2M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$9.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.87M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$5.78M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$5.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
-$37.5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$9.59M |
| 3 |
PA
Perceptive Advisors
New York
|
-$6.35M |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
-$5.13M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$5.09M |
TVTX Hedge Fund Activity: Q1 2019 in Review
131 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q1 2019, worth a combined $964M — up 3.2% from $934M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new TVTX positions and 14 closed out — a net gain of 1 holder — while 54 added to existing stakes and 38 trimmed.
The largest buyer was Deutsche Bank, adding an estimated $14.2M. The largest seller was Scopia Capital Management, cutting an estimated $37.5M.
- 131 institutional investors held Travere Therapeutics (TVTX) as of Q1 2019, up from 130 in Q4 2018.
- Funds reported $964M of Travere Therapeutics stock for Q1 2019, up 3.2% quarter-over-quarter.
- 15 funds opened new Travere Therapeutics positions in Q1 2019 and 14 closed out, a net change of +1 holder.
- The largest Travere Therapeutics buyer in Q1 2019 was Deutsche Bank, an estimated $14.2M added.
- The largest Travere Therapeutics seller in Q1 2019 was Scopia Capital Management, an estimated $37.5M sold.
Based on aggregated 13F filings for Q1 2019.